scPharmaceuticals (NASDAQ:SCPH) Earns “Buy” Rating from HC Wainwright

scPharmaceuticals (NASDAQ:SCPH)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 448.78% from the company’s previous close.

Separately, Craig Hallum lowered their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

scPharmaceuticals Stock Up 1.2 %

Shares of SCPH stock opened at $3.28 on Monday. The firm’s fifty day moving average price is $3.40 and its two-hundred day moving average price is $3.99. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 1 year low of $3.08 and a 1 year high of $6.28. The firm has a market capitalization of $164.13 million, a P/E ratio of -1.73 and a beta of 0.11.

Hedge Funds Weigh In On scPharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SCPH. Thrivent Financial for Lutherans raised its position in scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after acquiring an additional 14,866 shares in the last quarter. King Luther Capital Management Corp raised its holdings in shares of scPharmaceuticals by 0.9% in the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after purchasing an additional 20,650 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals in the 3rd quarter valued at about $57,000. BNP Paribas Financial Markets grew its holdings in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after purchasing an additional 3,101 shares during the period. Finally, Rubric Capital Management LP increased its position in scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after buying an additional 1,250,000 shares during the last quarter. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.